110997-83-6

Basic information

• Product Name: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline
• Synonyms: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline
• CAS NO: 110997-83-6
• Molecular Weight: 257.332
• Mol File: 110997-83-6.mol

Chemical Properties

• CAS DataBase Reference: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline(110997-83-6)
• EPA Substance Registry System: 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline(110997-83-6)

Safety Data

• Hazardous Substances Data: 110997-83-6(Hazardous Substances Data)

Upstream product

• 56766-90-6 1-(3,4-dimethoxyphenyl)-2-(4-nitrophenyl)ethan-1-one 
• 104-03-0 4-nitrobenzeneacetic acid 
• 51042-54-7 1,2-Dimethoxy-4-[2-(4-nitrophenyl)ethenyl]benzene 
• 110997-71-2 1,2-dimethoxy-4-[2-(4-nitrophenyl)ethenyl]benzene 
• 50434-36-1 4-nitrophenylacetyl chloride 

Downstream Products

• 110998-05-5 N-formyl-4-[2-(3,4-dimethoxyphenyl)ethyl]benzeneamine 
• 110997-07-4 N-[4-[2-(3,4-Dimethoxyphenyl)ethyl]phenyl]-2-hydroxy-4-methylbenzamide 
• 110997-46-1 N-[4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl]-2-hydroxybenzamide 
• 1670-84-4 1H-indole-2-carboxamide 
• 1186335-59-0 N-{4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl}phthalimide 
• 1186335-65-8 4,5,6,7-tetrachloro-N-{4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl}phthalimide 
• 313676-48-1 2-[[4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl]amino]benzoic acid 
• 110997-10-9 3-Hydroxy-biphenyl-4-carboxylic acid {4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-amide 
• 110997-67-6 2-Hydroxy-naphthalene-1-carboxylic acid {4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-amide 
• 110997-40-5 1-Hydroxy-naphthalene-2-carboxylic acid {4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-amide 
• 110997-18-7 5-Bromo-N-{4-[2-(3,4-dimethoxy-phenyl)-ethyl]-phenyl}-2-hydroxy-benzamide 
• 110997-19-8 4-chloro-N-[4-[2-(3,4-dimethoxyphenyl)ethyl]phenyl]-2-hydroxybenzamide 

Relevant articles and documents

Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer

A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 μM) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 μM. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC 50 1.7 μM and 0.27 μM, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer.

Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide

Swine-origin influenza A virus has caused pandemics throughout the world and influenza A is regarded as a serious global health issue. Hence, novel drugs that will target these viruses are very desirable. Influenza A expresses an RNA polymerase essential for its transcription and replication which comprises PA, PB1, and PB2 subunits. We identified potential novel anti-influenza agents from a screen of 34 synthesized phenethylphenylphthalimide analogs derived from thalidomide (PPT analogs). For this screen we used a PA endonuclease inhibition assay, a PB2 pathogenicity-determinant domain-binding assay, and an anti-influenza A virus assay. Three PPT analogs, PPT-65, PPT-66, and PPT-67, were found to both inhibit PA endonuclease activity and retard the growth of influenza A, suggesting a correlation between their activities. PPT-28 was also found to inhibit the growth of influenza A. These four analogs have a 3,4-dihydroxyphenethyl group in common. We also discuss the possibility that 3,4-dihydroxyphenethyl group flexibility may play an important functional role in PA endonuclease inhibition. Another analog harboring a dimethoxyphenethyl group, PPT-62, showed PB2 pathogenicity-determinant domain-binding activity, but did not inhibit the growth of the virus. Our present results indicate the utility of the PA endonuclease assay in the screening of anti-influenza drugs and are therefore useful for future strategies to develop novel anti-influenza A drugs and for mapping the function of the influenza A RNA polymerase subunits.

Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists

Liver X receptor (LXR) α/β dual agonists are candidate medicaments for the treatment of metabolic syndrome, because their biological actions include increasing cholesterol efflux mediated by LXRβ. However, their clinical application is currently limited by their enhancing effect on triglyceride (TG) synthesis mediated by LXRα. Combination of an LXRα-selective antagonist with an LXRα/β dual agonist may overcome this disadvantage. In the present work, structural development studies of phenethylphenyl phthalimide 9, which possesses LXRα/β dual-antagonistic activity and α-glucosidase-inhibitory activity, led to the LXRα-selective antagonist 23f. Specific α-glucosidase inhibitors were also obtained.

Method of inhibiting amyloid protein aggregation and imaging amyloid deposits

The present invention provides a method of treating Alzheimer's disease using a compound of Formula I Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of Formula I and a method of imaging amyloid deposits, as we

Catechol based inhibitors of 15-lipoxygenase

A potent 15-lipoxygenase (15-LO) inhibitor, compound 6, was identified by mass screening the Parke-Davis compound portfolio. The active moiety of compound 6 was determined to be the catechol functionality. Additional analogs were prepared and analyzed for inhibitory activity against 5-, 12-, and 15-lipoxygenase.

N-SUBSTITUTED-2-HYDROXY-ALPHA-OXO-BENZENEACETAMIDES AND PHARMACEUTICAL COMPOSITIONS HAVING ACTIVITY AS MODULATORS OF THE ARACHIDONIC ACID CASCADE

The present invention relates to novel N-substituted 2-hydroxybenzamide and N-substituted 2-hydroxy-alpha-oxo-benezene acetamide compounds pharmaceutical compositions, and methods of use for therefore for the treatment of diseases in which products having lipoxygenase enzyme activity contribute to the pathological condition. Selected novel intermediates are also the present invention

Enolamides, pharmaceutical compositions and methods for treating inflammation

The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the